Interpace Diagnostics Group, Inc. Note Agreements

Subordinated Convertible Promissory Note to BroadOak Fund V, L.P., dated May 5, 2022 (Filed With SEC on May 10, 2022)

Amendment to Secured Promissory Note dated May 10, 2021 with1315 Capital II, L.P (Filed With SEC on August 11, 2021)

Amendment to Secured Promissory Note dated May 10, 2021 with Ampersand 2018 Limited Partnership (Filed With SEC on August 11, 2021)

Promissory Note entered into between the Company and 1315 Capital II, L.P, dated January 7, 2021 (Filed With SEC on May 11, 2021)

Promissory Note entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021 (Filed With SEC on May 11, 2021)

Subordinated Seller Note of Interpace BioPharma, Inc., dated July 15, 2019, in favor of Cancer Genetics, Inc (Filed With SEC on July 19, 2019)

INTERPACE DIAGNOSTICS GROUP, INC. SENIOR SECURED CONVERTIBLE NOTE (Filed With SEC on April 18, 2017)

Interpace Diagnostics Group, Inc. Senior Secured Convertible Note (Filed With SEC on March 23, 2017)

Interpace Diagnostics Group, Inc. Senior Secured Note (Filed With SEC on March 23, 2017)

FIFTH AMENDMENT TO NON-NEGOTIABLE SUBORDINATED SECURED PROMISSORY NOTE (Filed With SEC on November 17, 2016)

FOURTH AMENDMENT TO NON-NEGOTIABLE SUBORDINATED SECURED PROMISSORY NOTE (Filed With SEC on November 3, 2016)

THIRD AMENDMENT TO NON-NEGOTIABLE SUBORDINATED SECURED PROMISSORY NOTE (Filed With SEC on October 4, 2016)

AMENDMENT NO. 1 TO NOTE (Filed With SEC on November 12, 2015)

LIMITED WAIVER, CONSENT AND AMENDMENT NO. 2 TO NOTE (Filed With SEC on November 2, 2015)